EPISODE · Mar 25, 2021 · 54 MIN
S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment
from Surfing the MASH Tsunami · host HEP Dynamics LLC
Send us Fan MailMazen Noureddin joins the Surfers to discuss his work determining cost effectiveness of Non-Invasive Testing in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues. Dr. Noureddin starts the discussion by providing a history of cost-effectiveness research in NASH and NAFLD. At a population level, biopsy turns out never to be cost-effective while less expensive tests almost always are. As the group brainstormed implications and new questions, they touched on theories on how cost-effectiveness for F3 and F2 patients might differ, and even how chronic therapies and sequential use of specific medicines might reflect cost-effectiveness issues. An enlightening way to think about testing and treatment today, and how these will evolve over time.
Embed this episode
What this episode covers
Send us Fan Mail Mazen Noureddin joins the Surfers to discuss his work determining cost effectiveness of Non-Invasive Testing in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues. Dr. Noureddin starts the discussion by providing a history of cost-effectiveness research in NASH and NAFLD. At a population level, biopsy turns out never to be cost-effective while less expensive tests almost always are. As the group brainstormed impli...
NOW PLAYING
S2-E16 -- Cost-Effectiveness of Widespread Non-Invasive NASH Testing and Treatment
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.